Clinical trials: Alcoholic Liver Disease
Nonalcoholic Steatohepatitis
Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis
This study will be a randomized, controlled, parallel study that aims to evaluate the efficacy and safety of Rosuvastatin versus Coenzyme Q10 on nonalcoholic steatohepatitis patients.
- Trial name
- NCT05731596
- Testing
- Rosuvastatin 20 Mg Oral Tablet, Coenzyme Q10 100 MG Oral Capsule
- Volunteers
- 46 people
- Sponsor
- Tanta University
Hepatic Disease
Ketotifen in Non-Alcoholic Fatty Liver Disease Patients
The aim of this study is to investigate the safety and efficacy of using ketotifen in patients with NAFLD patients without cirrhosis
- Trial name
- NCT05616442
- Testing
- Ketotifen, Vitamin E
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease, Obesity
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restricted control diet.
- Trial name
- NCT05268042
- Testing
- Moderately carbohydrate-restricted diet, Fat-restricted diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Alabama at Birmingham
Fatty Liver
Effect of Focused Ultrasound on Abdominal and Intrahepatic Fat in Patients With Non-alcoholic Fatty Liver Disease
In recent years, a number of modalities have become available for the noninvasive reduction of adipose tissue. One of those is high intensity focused ultra sound (HIFU).
- Trial name
- NCT04161703
- Testing
- focused ultrasound, diet and exercise, diet and exercise
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
NASH - Nonalcoholic Steatohepatitis, NAFLD
NASH in Subjects With Different Classes of Obesity
It is an observational trial on 500 subjects. The purpose of this trial is to assess the prevalence of non-alcoholic steatohepatitis (NASH) in subjects with different classes of obesity.
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, Obesity, Obesity, Morbid
- Trial name
- CONNECT (NCT04653103)
- Testing
- Liver biopsy
- Where
- 2 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Catholic University of the Sacred Heart
NAFLD, NASH With Fibrosis
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
- Conditions
- NAFLD, NASH With Fibrosis, Liver Fibrosis
- Trial name
- NCT05506488
- Testing
- Dasatinib 100 MG + Quercetin (1000 MG)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NAFLD- Non Alcoholic Fatty Liver Disease
Study of Neutrophils and Circulating Platelets in Correlation With the Activity of T Lymphocytes in Patients With NAFLD (Nonalcoholic Fatty Liver Disease)
The aim of the study is to define the relationship between neutrophils, platelets and the activity of T lymphocytes in patients with NAFLD (nonalcoholic fatty liver disease).
- Trial name
- NAFLD (NCT05358496)
- Testing
- Data collection
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of L'Aquila
Non-Alcoholic Fatty Liver Disease, Obesity
Alternate Day Fasting, Exercise, and NAFLD
Approximately 65% of obese individuals have non-alcoholic fatty liver disease (NAFLD), and this condition is strongly related to the development of insulin resistance and diabetes.
- Trial name
- NCT04004403
- Testing
- Alternate day fasting, Exercise
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Non-alcoholic Fatty Liver Disease
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
The primary objective of this trial is to investigate the relative Bioavailability (BA) of tablet formulation of Dabigatran etexilate (DE) with and without co-administration of rabeprazole in healthy male subjects.
- Trial name
- NCT03143166
- Testing
- Dabigatran Etexilate, Rabeprazol sodium
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Nonalcoholic Steatohepatitis, Liver Steatosis
Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis
The investigators hypothesize that Nigella Sativa will have an effect on Nonalcoholic Steatohepatitis and Liver Steatosis by enhancing lipophagy in the liver tissue.
- Trial name
- NASH NAFLD (NCT02307344)
- Testing
- Nigella Sativa
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Hillel Yaffe Medical Center
Non-alcoholic Steatohepatitis (NASH)
Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)
The purpose of the study was to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH
- Trial name
- FLIGHT-FXR (NCT02855164)
- Testing
- Tropifexor (LJN452)
- Where
- 81 sites in United States, Argentina and 15 more
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
Fasting, Intermittent, Diet
Intermittent Fasting Versus Diet to Stop Hypertension on Metabolic Risk Profile in Nonalcoholic Fatty Liver Patients
This study was conducted to compare between the effect of intermittent fasting and diatery approach to stop hypertension on metabolic risk profile in nonalcoholic fatty liver patients.
- Conditions
- Fasting, Intermittent, Diet, Hypertension, Metabolic Syndrome
- Trial name
- NCT06666894
- Testing
- Intermittent fasting, Dietary approach to stop hypertension (DASH)
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Non-Alcoholic Fatty Liver Disease
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
Lovaza is the only fish oil supplement approved by the FDA. It is available by prescription for the treatment of hypertriglyceridemia (> 500 mg/dl).
- Trial name
- NCT00941642
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Huntington Medical Research Institutes
Non-Alcoholic Fatty Liver Disease (NAFLD
Interest of APA in Fatty Liver Disease Evaluation of Efficacy and Adherence to an Adapted Physical Activity (APA) Program in Patients With Metabolic Fatty Liver Disease
Non-Alcoholic Fatty liver Disease (NAFLD) is a Public Health problem. NAFLD affects nearly 25% of the world's population. NAFLD includes hepatic complications related to insulin resistance and metabolic inflammation.
- Trial name
- STEATO-APA (NCT04835831)
- Testing
- adapted physical activity + Dietetic advice
- Where
- 2 sites in France
- Volunteers
- 115 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
NAFLD
Study of Losartan in the Treatment of NAFLD in Children
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease among children and is closely associated with obesity and the metabolic syndrome.
- Trial name
- NCT01913470
- Testing
- Losartan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Miriam Vos, MD
Non-alcoholic Steatohepatitis
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is…
- Trial name
- NCT03987451
- Testing
- Semaglutide
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Non-Alcoholic Steatohepatitis
A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of HEC96719 in non-cirrhotic NASH patients.
- Trial name
- NCT05397379
- Testing
- HEC96719
- Where
- 9 sites in China
- Volunteers
- 68 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.